Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

Levocloperastine with its dual mechanism of action acts on both the central bulbar cough centre and on peripheral receptors in the tracheobronchial tree. In preclinical studies, levocloperastine ...

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression of signals from nerves that promote bone marrow regeneration, according to ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Fingernail-sized vibrating gadgets, similar to the tiny devices that make your cellphone buzz, could help people with ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

In recent years, the conversation surrounding cannabis and its medicinal properties has gained considerable momentum.

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...